Journal of Bioequivalence & Bioavailability

Corporate integrity in the medical research and pharmaceuticals industries: The SECs Whistleblower Program

Joint Event on 4^th International Conference on Drug Discovery, Designing Chemistry and Pharmaceutical Analysis & International Conference on Biobetters and Regulatory Affairs

June 27-28, 2018 | Vancouver, Canada

Steven J Durham

Labaton Sucharow LLP, USA

Keynote: J Bioequiv Availab

Abstract:

In 2010, the Dodd-Frank reform legislation created the SEC Whistleblower Program as a key tool in the SEC???s enforcement framework. Since its inception, the SEC???s Office of the whistleblower has awarded 50 whistleblowers over $160 million for information that has led to many significant SEC enforcement actions. In this keynote address, Labaton Sucharow partner Steven J. Durham will discuss the operation and success of the SEC Whistleblower Program and how every individual plays an important role in protecting corporate integrity.

Biography :

At Labaton Sucharow, Steve Durham concentrates his practice on representing corporate whistleblowers before the SEC. With a 25 year track record of protecting whistleblower and victim rights as a federal prosecutor and as a senior corporate compliance attorney, Steve helps clients obtain justice and maximize recoveries through the SEC Whistleblower Program. During his two decade tenure as an Assistant United States Attorney in Washington, D.C., Steve was a founding member of the President’s financial fraud enforcement task force and longtime chief and deputy chief of the fraud and public corruption section. As a prosecutor and section chief, his experience included a broad array of complex white collar cases and numerous parallel enforcement actions with the SEC involving corrupt broker-dealer violations, offering frauds, market manipulations, Ponzi schemes, insider trading infractions, FCPA violations and accounting frauds.

E-mail: sdurham@labaton.com